The effects of total‐body hyperthermia combined with anticancer drugs on immunity in advanced cancer patients

As total‐body hyperthermia (TBHT) therapy may lead to a reduction in the immune response of cancer patients because of the immediate effect of heat on lymphocytes, the authors studied the immunity of advanced cancer patients receiving combined TBHT and anticancer chemotherapy. A decrease was found i...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1983-10, Vol.52 (7), p.1173-1177
Main Authors: Koga, Shigemasa, Izumi, Akio, Maeta, Michiro, Shimizu, Norio, Osaki, Yukio, Kanayama, Hirotomo
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Complement System Proteins - analysis
Cyclophosphamide - administration & dosage
Doxorubicin - administration & dosage
Female
Fever - physiopathology
Fluorouracil - administration & dosage
Gastrointestinal Neoplasms - immunology
Hot Temperature - therapeutic use
Humans
Immunity - drug effects
Immunoglobulins - analysis
Induced hyperthermia. Cryotherapy
Lymphocytes - immunology
Male
Medical sciences
Middle Aged
Mitomycin
Mitomycins - administration & dosage
Neoplasms - drug therapy
Neoplasms - immunology
Neoplasms - therapy
Treatment with physical agents
Treatment. General aspects
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As total‐body hyperthermia (TBHT) therapy may lead to a reduction in the immune response of cancer patients because of the immediate effect of heat on lymphocytes, the authors studied the immunity of advanced cancer patients receiving combined TBHT and anticancer chemotherapy. A decrease was found in their lymphocyte blastogenesis, skin reactions to PPD and PHA, lymphocyte rosette formation, IgG, and C3c component. These parameters returned to their pretreatment levels at 1 week after completion of TBHT therapy. This result indicates that there is no necessity for giving special consideration to a reduction of cell‐mediated immunity in TBHT therapy.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19831001)52:7<1173::AID-CNCR2820520708>3.0.CO;2-0